The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
This article reflects the scientific assessment of Mylotarg (gemtuzumab ozogamicin; Pfizer, New York City, NY) use for the treatment of acute myeloid leukemia based on important contributions from the rapporteur and co-rapporteur assessment teams, Committee for Medicinal Products for Human Use members, and additional experts following the application for a marketing authorization from the company. It's a unique opportunity to look at the data from a regulatory point of view and the importance of assessing the benefit-risk.
PMID: 30898889 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Ali S, Dunmore HM, Karres D, Hay JL, Salmonsson T, Gisselbrecht C, Sarac SB, Bjerrum OW, Hovgaard D, Barbachano Y, Nagercoil N, Pignatti F Tags: Oncologist Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | European Medicines Agency (EMA) | Leukemia | Marketing | Pfizer | Study | Websites